Search results
Showing 1 to 12 of 12 results for epcoritamab
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment in adults.
In development Reference number: GID-TA11768 Expected publication date: 28 October 2026
Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma (DLBCL) [TSID12334]
Topic prioritisation
In development Reference number: GID-TA11590 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 12 August 2026.
In development Reference number: GID-TA11488 Expected publication date: TBC
This guideline covers diagnosing, staging and managing non-Hodgkin lymphoma (NHL) in people aged 16 years and over. It includes radiotherapy, systemic anticancer therapy and stem cell transplantation treatments for follicular, MALT, mantle cell, diffuse large B-cell, Burkitt and peripheral T-cell lymphoma.
Epcoritamab with R-CHOP for newly diagnosed diffuse large B-cell lymphoma [ID6701]
Awaiting development Reference number: GID-TA11935 Expected publication date: TBC
Awaiting development Reference number: GID-TA11590 Expected publication date: TBC
Evidence-based recommendations on glofitamab (Columvi) plus gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in adults.
Evidence-based recommendations on lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory large B-cell lymphoma in adults after first-line chemoimmunotherapy when a stem cell transplant is suitable.